- Home
- KOD vs DHF Comparison
KOD vs DHF Comparison
Compare KOD & DHF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KOD
- DHF
- Stock Information
- Founded
- KOD 2009
- DHF 1998
- Country
- KOD United States
- DHF United States
- Employees
- KOD N/A
- DHF N/A
- Industry
- KOD Biotechnology: Biological Products (No Diagnostic Substances)
- DHF Finance Companies
- Sector
- KOD Health Care
- DHF Finance
- Exchange
- KOD Nasdaq
- DHF Nasdaq
- Market Cap
- KOD 198.4M
- DHF 172.4M
- IPO Year
- KOD 2018
- DHF N/A
- Fundamental
- Price
- KOD $8.84
- DHF $2.58
- Analyst Decision
- KOD Hold
- DHF
- Analyst Count
- KOD 3
- DHF 0
- Target Price
- KOD $9.00
- DHF N/A
- AVG Volume (30 Days)
- KOD 549.8K
- DHF 451.1K
- Earning Date
- KOD 08-13-2025
- DHF 01-01-0001
- Dividend Yield
- KOD N/A
- DHF 7.65%
- EPS Growth
- KOD N/A
- DHF N/A
- EPS
- KOD N/A
- DHF N/A
- Revenue
- KOD N/A
- DHF N/A
- Revenue This Year
- KOD N/A
- DHF N/A
- Revenue Next Year
- KOD N/A
- DHF N/A
- P/E Ratio
- KOD N/A
- DHF N/A
- Revenue Growth
- KOD N/A
- DHF N/A
- 52 Week Low
- KOD $1.92
- DHF $2.06
- 52 Week High
- KOD $11.60
- DHF $2.39
- Technical
- Relative Strength Index (RSI)
- KOD 84.50
- DHF 53.88
- Support Level
- KOD $5.00
- DHF $2.57
- Resistance Level
- KOD $5.73
- DHF $2.60
- Average True Range (ATR)
- KOD 0.70
- DHF 0.02
- MACD
- KOD 0.42
- DHF -0.00
- Stochastic Oscillator
- KOD 99.61
- DHF 45.45
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.
About DHF BNY Mellon High Yield Strategies Fund
BNY Mellon High Yield Strategies Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income and its secondary objective is capital appreciation. It invests predominantly in fixed-income securities of below-investment-grade credit quality.